FDA Brief

Warning letters Drugs

FDA warning letter to

Accu Bio-Chem Laboratories

MediumIssued Feb 24, 2022Posted Mar 15, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.

What happened

FDA inspected the contract testing laboratory in Glendale, California, from August 24 to 31, 2021. FDA found that the lab did not adequately investigate out-of-specification (OOS, outside the set limit) assay (active-ingredient content) results for OTC drugs; it retested new sample preparations without first finding a root cause. FDA also found unverified chemical and microbiological test methods and electronic systems that could allow data deletion or lacked audit trails (records of changes).

What FDA found

  1. The firm did not thoroughly investigate outside-limit test results for active ingredient content; it prepared and tested new samples without first establishing a root cause.

    21 CFR 211.192
  2. The firm did not verify that its chemical and microbiological test methods were accurate and suitable for each OTC drug product.

    21 CFR 211.165(e)
  3. The firm's electronic systems lacked controls to prevent data deletion and to record all changes through audit trails (records of changes).

    21 CFR 211.68(b)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with corrections and preventive actions, including a retrospective OOS review, a method suitability assessment, and data-system audit-trail and corrective-action plans. If it cannot finish within 15 working days, it must give reasons and a completion schedule.

Who should pay attention

  • drug manufacturers that use this lab for release or stability testing
  • brands selling OTC drugs tested by this lab
  • quality teams relying on contract lab data for batch release

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk